4 unknown, 2 completed, 2 recruiting, 1 terminated. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Completed 2, Recruiting 2, Terminated 1 |
| Phase 1 | 4 | Unknown 2, Completed 1, Recruiting 1 |
Follow Soft-Tissue Sarcoma: new trials by email Literature Review of Soft-Tissue Sarcoma trials Research Report on Soft-Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma Zanzalintinib, Pembrolizumab - Phase 2, Zanzalintinib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 20 | 2026-04-14 | 2026-11-02 |
| Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies Spedox-6, Pegfilgrastim, Filgrastim - Soft-tissue Sarcoma, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 67 | 2025-04-30 | 2026-07-17 |
| Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma Compound 451238 - Soft-tissue Sarcoma | Phase 1 / Phase 2 | Completed | Royal Marsden NHS Foundation Trust | 12 | 2018-11-05 | 2026-03-02 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. Palbociclib - Soft-tissue Sarcoma, Osteosarcoma | Phase 2 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 40 | 2017-03-31 | 2024-01-23 |
| Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas TAK-228 - Soft-tissue Sarcoma | Phase 2 | Terminated | Fox Chase Cancer Center | 6 | 2017-02-21 | 2022-10-14 |
| A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma Ribociclib - Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated | Phase 2 | Unknown | Assaf-Harofeh Medical Center | 30 | 2016-07-01 | 2017-10-25 |
| A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide - Solid Tumors, Soft-tissue Sarcoma | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 197 | 2015-09-18 | 2022-02-02 |
| High Precision RT For Soft-Tissue Sarcoma Intensity-Modulated Radiotherapy, Daily Cone Beam CT - Soft-Tissue Sarcoma | Phase 2 | Completed | University Health Network, Toronto | 26 | 2011-06-01 | 2022-10-07 |
Sarcoma (9) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Lipoma (1) · Liposarcoma (1) · Liposarcoma, Myxoid (1) · Mesothelioma, Malignant (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Connective and Soft Tissue (9) · Breast Diseases (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Breast Neoplasms (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lung Diseases (2)
Clinical Trials, Phase II as Topic (1) · Cyclophosphamide (1) · Filgrastim (1) · Radiotherapy, Intensity-Modulated (1) · avelumab (1) · palbociclib (1) · pegfilgrastim (1) · pembrolizumab (1) · regorafenib (1) · ribociclib (1) · sapanisertib (1)
Institut Bergonié (2) · Assaf-Harofeh Medical Center (1) · Fox Chase Cancer Center (1) · Grupo Espanol de Investigacion en Sarcomas (1) · M.D. Anderson Cancer Center (1) · Royal Marsden NHS Foundation Trust (1) · University Health Network, Toronto (1) · University of California, Irvine (1)
United States (3) · France (2) · Canada (1) · Israel (1) · Spain (1) · United Kingdom (1)
Anna Estival (1) · Antonio Casado (1) · Charles Catton, MD (1) · Claudia Valverde (1) · Daniela Katz, M.D (1) · Diego Jara, MD (1) · Isabel Sevilla, MD (1) · Javier Lavernia (1)
PMID 34965951, PMID 34998048, PMID 40204996, PMID 40579407
2014 (1), 2016 (1), 2017 (1)